老年晚期肝细胞癌的系统治疗
Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults.
作者信息
Arellano Luisa M, Arora Sukeshi Patel
机构信息
Mays Cancer Center, UT Health Science Center San Antonio, 7979 Wurzbach Rd, MC 8026, San Antonio, TX 78229, USA.
出版信息
J Nat Sci. 2018 Aug;4(8).
Abstract
Over the past 30 years, the incidence in of hepatocellular carcinoma (HCC) in the United States has tripled, largely due to untreated chronic Hepatitis C virus, alcoholic hepatitis, and non-alcoholic steatohepatitis (NASH). Additionally, the incidence of HCC among South Texas Hispanics is higher than elsewhere in the United States. The median age of HCC is 62 years in United States and 67 years in South Texas, with over 30% being 70 years of age or older. However, there is limited data on how to treat older adults with advanced HCC. In this review, we will discuss treatment options for older adults with advanced HCC, further emphasizing the need for prospective studies in this population.
摘要
在过去30年里，美国肝细胞癌（HCC）的发病率增长了两倍，这主要归因于未经治疗的慢性丙型肝炎病毒、酒精性肝炎和非酒精性脂肪性肝炎（NASH）。此外，南德克萨斯州西班牙裔人群中HCC的发病率高于美国其他地区。在美国，HCC患者的中位年龄为62岁，在南德克萨斯州为67岁，其中超过30%的患者年龄在70岁及以上。然而，关于如何治疗老年晚期HCC患者的数据有限。在本综述中，我们将讨论老年晚期HCC患者的治疗选择，并进一步强调在这一人群中开展前瞻性研究的必要性。
相似文献
1
Systemic Treatment of Advanced Hepatocellular Carcinoma in Older Adults.老年晚期肝细胞癌的系统治疗
J Nat Sci. 2018 Aug;4(8).
2
Hepatocellular carcinoma and other complications of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Japan: A structured review of published works.日本肝细胞癌及非酒精性脂肪性肝病和非酒精性脂肪性肝炎的其他并发症：已发表作品的结构化综述
Hepatol Res. 2021 Jan;51(1):19-30. doi: 10.1111/hepr.13583. Epub 2020 Dec 9.
3
A comparison of survival and pathologic features of non-alcoholic steatohepatitis and hepatitis C virus patients with hepatocellular carcinoma.非酒精性脂肪性肝炎和丙型肝炎病毒患者肝细胞癌的生存和病理特征比较。
World J Gastroenterol. 2012 Aug 21;18(31):4145-9. doi: 10.3748/wjg.v18.i31.4145.
4
Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.非酒精性脂肪性肝炎与丙型肝炎和酒精性肝病患者行根治性治疗的肝细胞癌结局比较。
Hepatology. 2012 Jun;55(6):1809-19. doi: 10.1002/hep.25536. Epub 2012 Apr 23.
5
Frontline therapy for advanced hepatocellular carcinoma: an update.晚期肝细胞癌的一线治疗：最新进展
Therap Adv Gastroenterol. 2022 Apr 11;15:17562848221086126. doi: 10.1177/17562848221086126. eCollection 2022.
6
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic?非酒精性脂肪性肝炎相关肝细胞癌：流行趋势的有力证据？
Hepatol Res. 2012 Jan;42(1):1-14. doi: 10.1111/j.1872-034X.2011.00872.x. Epub 2011 Sep 15.
7
Hepatocellular carcinoma in non-alcoholic steatohepatitis: Current knowledge and implications for management.非酒精性脂肪性肝炎中的肝细胞癌：当前认知及管理意义
World J Hepatol. 2017 Apr 18;9(11):533-543. doi: 10.4254/wjh.v9.i11.533.
8
Nonalcoholic Steatohepatitis Is the Most Rapidly Increasing Indication for Liver Transplantation in the United States.非酒精性脂肪性肝炎是美国肝移植增长最快的适应证。
Clin Gastroenterol Hepatol. 2021 Mar;19(3):580-589.e5. doi: 10.1016/j.cgh.2020.05.064. Epub 2020 Jun 9.
9
Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma.非酒精性脂肪性肝炎与酒精相关肝细胞癌的比较。
Clin Mol Hepatol. 2020 Apr;26(2):196-208. doi: 10.3350/cmh.2019.0012. Epub 2020 Jan 9.
10
Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.非酒精性脂肪性肝病相关肝细胞癌的临床特征：一项人体研究综述
Clin J Gastroenterol. 2015 Feb;8(1):1-9. doi: 10.1007/s12328-014-0548-5. Epub 2015 Jan 10.
引用本文的文献
1
DLGAP4 acts as an effective prognostic predictor for hepatocellular carcinoma and is closely related to tumour progression.DLGAP4 可作为肝细胞癌的有效预后预测因子，与肿瘤进展密切相关。
Sci Rep. 2022 Nov 17;12(1):19775. doi: 10.1038/s41598-022-23837-y.
2
Hospital Frailty Risk Score Is Independently Associated with Mortality and Encephalopathy in Hospitalized Patients with Hepatocellular Carcinoma.医院虚弱风险评分与肝细胞癌住院患者的死亡率和脑病独立相关。
Biomedicines. 2021 Nov 15;9(11):1693. doi: 10.3390/biomedicines9111693.
3
Expression pattern and prognostic value of N6-methyladenosine RNA methylation key regulators in hepatocellular carcinoma.N6-甲基腺苷 RNA 甲基化关键调控因子在肝细胞癌中的表达模式及预后价值。
Mutagenesis. 2021 Oct 6;36(5):369-379. doi: 10.1093/mutage/geab032.
4
Efficacy and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma.索拉非尼治疗老年晚期肝细胞癌患者的疗效和安全性。
Clinics (Sao Paulo). 2021 Jan 22;76:e2498. doi: 10.6061/clinics/2021/e2498. eCollection 2021.
5
Prognostic Value of an m6A RNA Methylation Regulator-Based Signature in Patients with Hepatocellular Carcinoma.基于 m6A RNA 甲基化调控因子的signature 在肝癌患者中的预后价值。
Biomed Res Int. 2020 Jul 15;2020:2053902. doi: 10.1155/2020/2053902. eCollection 2020.
6
Hepatocellular carcinoma in older adults: A comprehensive review by Young International Society of Geriatric Oncology.老年肝细胞癌：国际老年肿瘤学会青年委员会的全面综述
J Geriatr Oncol. 2020 May;11(4):557-565. doi: 10.1016/j.jgo.2019.10.007. Epub 2019 Nov 6.
本文引用的文献
1
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.卡博替尼治疗晚期和进展性肝细胞癌患者。
N Engl J Med. 2018 Jul 5;379(1):54-63. doi: 10.1056/NEJMoa1717002.
2
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.乐伐替尼与索拉非尼用于不可切除肝细胞癌患者一线治疗的比较：一项随机、III 期非劣效性试验。
Lancet. 2018 Mar 24;391(10126):1163-1173. doi: 10.1016/S0140-6736(18)30207-1.
3
Hepatocellular carcinoma in elderly: Clinical characteristics, treatments and outcomes compared with younger adults.老年肝细胞癌：与年轻成年人相比的临床特征、治疗及结局
PLoS One. 2017 Sep 8;12(9):e0184160. doi: 10.1371/journal.pone.0184160. eCollection 2017.
4
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.纳武利尤单抗治疗晚期肝细胞癌患者（CheckMate 040）：一项开放标签、非对照、1/2 期剂量递增和扩展试验。
Lancet. 2017 Jun 24;389(10088):2492-2502. doi: 10.1016/S0140-6736(17)31046-2. Epub 2017 Apr 20.
5
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.regorafenib 用于索拉非尼治疗后进展的肝细胞癌患者（RESORCE）：一项随机、双盲、安慰剂对照、3 期试验。
Lancet. 2017 Jan 7;389(10064):56-66. doi: 10.1016/S0140-6736(16)32453-9. Epub 2016 Dec 6.
6
Hepatocellular carcinoma in elderly patients: challenges and solutions.老年肝细胞癌：挑战与解决方案。
J Hepatocell Carcinoma. 2016 Jun 17;3:9-18. doi: 10.2147/JHC.S101448. eCollection 2016.
7
Validation of a Prediction Tool for Chemotherapy Toxicity in Older Adults With Cancer.老年癌症患者化疗毒性预测工具的验证
J Clin Oncol. 2016 Jul 10;34(20):2366-71. doi: 10.1200/JCO.2015.65.4327. Epub 2016 May 16.
8
Cellular Senescence as the Causal Nexus of Aging.细胞衰老作为衰老的因果关联
Front Genet. 2016 Feb 12;7:13. doi: 10.3389/fgene.2016.00013. eCollection 2016.
9
Comparative dosing and efficacy of sorafenib in hepatocellular cancer patients with varying liver dysfunction.索拉非尼在不同肝功能损害的肝细胞癌患者中的剂量比较及疗效观察
J Gastrointest Oncol. 2015 Jun;6(3):259-67. doi: 10.3978/j.issn.2078-6891.2015.005.
10
Effect of cytotoxic chemotherapy on markers of molecular age in patients with breast cancer.细胞毒性化疗对乳腺癌患者分子年龄标志物的影响。
J Natl Cancer Inst. 2014 Apr;106(4):dju057. doi: 10.1093/jnci/dju057. Epub 2014 Mar 28.
Zotero 插件